Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study.
Familial papillary microcarcinoma
Familial papillary thyroid carcinoma
Papillary thyroid carcinoma
Papillary thyroid microcarcinoma
Recurrence
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
13
12
2021
accepted:
05
10
2022
pubmed:
18
10
2022
medline:
25
2
2023
entrez:
17
10
2022
Statut:
ppublish
Résumé
Familial papillary thyroid microcarcinoma (FPTMC) can present a more aggressive behavior than the sporadic microcarcinoma. However, few studies have analyzed this situation. The objective is to analyze the recurrence rate of FPTMC and the prognostic factors which determine that recurrence in Spain. Spanish multicenter longitudinal analytical observational study was conducted. Patients with FPTMC received treatment with curative intent and presented cure criteria 6 months after treatment. Recurrence rate and disease-free survival (DFS) were analyzed. Two groups were analyzed: group A (no tumor recurrence) vs. group B (tumor recurrence). Ninety-four patients were analyzed. During a mean follow-up of 73.3 ± 59.3 months, 13 recurrences of FPTMC (13.83%) were detected and mean DFS was 207.9 ± 11.5 months. There were multifocality in 56%, bilateral thyroid involvement in 30%, and vascular invasion in 7.5%; that is to say, they are tumors with histological factors of poor prognosis in a high percentage of cases. The main risk factors for recurrence obtained in the multivariate analysis were the tumor size (OR: 2.574, 95% CI 1.210-5.473; p = 0.014) and the assessment of the risk of recurrence of the American Thyroid Association (ATA), both intermediate risk versus low risk (OR: 125, 95% CI 10.638-1000; p < 0.001) and high risk versus low risk (OR: 45.454, 95% CI 5.405-333.333; p < 0.001). FPTMC has a recurrence rate higher than sporadic cases. Poor prognosis is mainly associated with the tumor size and the risk of recurrence of the ATA.
Identifiants
pubmed: 36251077
doi: 10.1007/s00423-022-02704-4
pii: 10.1007/s00423-022-02704-4
pmc: PMC9722874
doi:
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3631-3642Informations de copyright
© 2022. The Author(s).
Références
Front Endocrinol (Lausanne). 2019 Jan 24;10:10
pubmed: 30733707
Am J Otolaryngol. 2019 Jul - Aug;40(4):560-563
pubmed: 31103218
World J Surg. 2016 Mar;40(3):516-22
pubmed: 26744340
Eur J Endocrinol. 2015 Jun;172(6):R253-62
pubmed: 25637073
Laryngoscope. 2004 Dec;114(12):2182-6
pubmed: 15564841
Mod Pathol. 2011 Apr;24 Suppl 2:S19-33
pubmed: 21455198
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Clin Endocrinol (Oxf). 2016 Apr;84(4):598-606
pubmed: 26191611
Ann Surg Oncol. 2016 Aug;23(8):2564-70
pubmed: 27020589
Langenbecks Arch Surg. 2016 Sep;401(6):839-49
pubmed: 27263038
Surgery. 2020 Jan;167(1):19-27
pubmed: 31627846
World J Surg Oncol. 2015 Mar 21;13:115
pubmed: 25889362
World J Surg. 2020 Feb;44(2):452-460
pubmed: 31605172
Eur J Surg Oncol. 2018 Mar;44(3):307-315
pubmed: 28343733
Biochim Biophys Acta. 2014 Dec;1846(2):468-76
pubmed: 25218916
World J Surg. 2002 Aug;26(8):897-902
pubmed: 11965446
Ann Surg Treat Res. 2017 Mar;92(3):129-135
pubmed: 28289666
Surgery. 2012 Feb;151(2):192-8
pubmed: 21497873
World J Surg. 2015 Aug;39(8):1930-5
pubmed: 25894401
Ann Surg. 2004 Jul;240(1):18-25
pubmed: 15213613
World J Surg. 2007 May;31(5):924-33
pubmed: 17429563
Lancet. 1999 Feb 20;353(9153):637-9
pubmed: 10030330
J Endocrinol Invest. 2019 Oct;42(10):1205-1213
pubmed: 30927240
Surgery. 2020 Jan;167(1):46-55
pubmed: 31526581
Ann Surg Oncol. 2019 Sep;26(9):2952-2958
pubmed: 31264119
Surgery. 2020 Jan;167(1):110-116
pubmed: 31543327